In a May 3 press release, Eli Lilly announced encouraging results from its latest study of its Alzheimer's drug candidate, donanemab.In the Phase 3 study, which included more than 1,000 people with early signs of Alzheimer's disease, people receiving donanemab experienced 35% slower cognitive decline, as measured on cognitive tests, than people receiving placebo.
#people #years #immediately #conversations #press-release #independently #effectiveness #beneficiaries #diversification
[
add
]
[
|
|
...
]